Cargando…
Serum S100A12 levels are correlated with clinical severity in patients with dermatomyositis-associated interstitial lung disease
OBJECTIVE: S100A12 is an emerging inflammatory disease biomarker. Interstitial lung disease (ILD) is a common, severe complication of dermatomyositis (DM). This study was performed to investigate the association between S100A12 and disease activity and prognosis in patients with DM-associated ILD (i...
Autores principales: | Lou, Yueyan, Zheng, Yu, Fan, Bijun, Zhang, Liyan, Zhu, Feng, Wang, Xiaodong, Chen, Zhiwei, Tan, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607057/ https://www.ncbi.nlm.nih.gov/pubmed/31865833 http://dx.doi.org/10.1177/0300060519887841 |
Ejemplares similares
-
Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease
por: Lou, Yueyan, et al.
Publicado: (2020) -
The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease
por: Lou, Yueyan, et al.
Publicado: (2021) -
Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
por: Fan, Bijun, et al.
Publicado: (2021) -
The cryobiopsy in interstitial lung diseases guided by probe‐based confocal laser endomicroscopy is feasible
por: Zheng, Yu, et al.
Publicado: (2023) -
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)